Bracco Imaging enters collaboration agreement with Philochem
Category: #health  By Pankaj Singh  Date: 2022-03-23
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Bracco Imaging enters collaboration agreement with Philochem

Philochem, Philogen Group’s subsidiary, and Bracco Imaging S.p.A. have reportedly signed a collaboration and license agreement to develop and promote a small organic molecule for imaging applications.

Bracco and Philogen share an Italian heritage and run globally in the biotech and pharmaceutical sectors. Philochem and Bracco will lead the development of advanced technologies for the discovery and maximization of small molecule ligands that allow unmatched sensitivity and specificity for solid tumor imaging.

According to Prof. Dr. Dario Neri, the CEO of the Philogen Group and the Member of the Board of Philochem, the new partnership will target the development and promotion of a small molecule for imaging applications which commits to enhance the diagnosis, monitoring, and staging of response-to-treatment for patients diagnosed with cancer.

Both firms are dedicated to product development and making it available to patients who may gain an advantage from it.

Speaking about the collaboration, Fulvio Renoldi Bracco, the CEO and Vice Chairman of Bracco Imaging cited that the partnership exhibits the company’s commitment to creating long-term value in medical imaging. The company has built a suite of leading products over the years for a prospering future in precision imaging.

For the unversed, Philochem is a completely owned subsidiary of the Philogen Group. Philogen is focused on discovering and developing novel biopharmaceutical and pharmaceutical products. The group’s strategy is to specifically deliver bioactive agents like cytokines, drugs, or radionuclides to the disease site using small organic ligands or antibodies.

This technology has produced a robust licensed pipeline of preclinical compounds and clinical-stage products in a suite of disease indications. The Siena-based firm has research activities at its subsidiary Philochem in Zurich. Philogen has inked agreements with multiple key pharmaceutical companies.

On the other hand, Bracco Imaging is a leading provider of diagnostic imaging that is headquartered in Milan. The company develops, produces, and promotes diagnostic imaging solutions and agents.

Source credit:

https://www.globenewswire.com/news-release/2022/03/22/2407265/0/en/Philochem-and-Bracco-Imaging-Announce-a-Collaboration-on-the-Development-of-a-Small-Molecule-for-Diagnostic-or-Medical-Imaging-Applications.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

By Pankaj Singh

Rona Therapeutics Inc has reportedly acquired the global exclusive rights to the siRNA platform of delivery moiety and chemical modification from Sanofi S.A., in addition to four pre-clinical contenders for unrevealed ...

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

By Pankaj Singh

California-based toy manufacturing and entertainment company, Mattel, has recently signed a multi-year agreement with Elon Musk’s private spaceflight company, SpaceX.

T...

USHV partners with Willowbrook to provide quality cardiovascular care

USHV partners with Willowbrook to provide quality cardiovascular care

By Pankaj Singh

US Heart & Vascular (USHV) is reportedly partnering with Willowbrook Cardiovascular Associates to offer quality cardiovascular care in the Houston market.

USHV has a strong ma...